<DOC>
	<DOCNO>NCT02097823</DOCNO>
	<brief_summary>The purpose study determine feasibility large trial compare olanzapine aprepitant obtain preliminary data effectiveness two medication treat nausea vomit child receive chemotherapy . Children receive 2 cycle chemotherapy high risk cause nausea vomit receive olanzapine one cycle aprepitant another cycle . Children randomize see medicine receive first . The investigator record number extra medication use nausea , number time child vomit , amount nausea child feel day .</brief_summary>
	<brief_title>Pilot Study Olanzapine Aprepitant Prevent Nausea Vomiting Children Receiving Chemotherapy</brief_title>
	<detailed_description>This pilot study , design randomize , crossover study compare olanzapine aprepitant pediatric oncology patient receive highly emetogenic chemotherapy ( HEC ) . The primary objective determine feasibility recruitment data collection conduct large trial aim compare olanzapine aprepitant antiemetic regimen establish efficacy regimen pediatric patient receive HEC . Secondary objective obtain preliminary data regard effectiveness olanzapine aprepitant well tolerability olanzapine pediatric oncology population . Each patient must plan undergo least 2 cycle cycle HEC . Each patient randomize receive olanzapine aprepitant first cycle chemotherapy , receive agent second cycle chemotherapy . Patients also receive ondansetron dexamethasone cycle . Patients CNS tumor receive dexamethasone . Response measure objectively record number emesis use breakthrough medication . The medication choose breakthrough medication treat physician discretion . A complete response episode emesis use breakthrough medication . A partial response one less episodes emesis one less use breakthrough medication . Nausea measure base parent patient scale separate measure , include compete partial response .</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>age great 4 year less 21 year patient receive least two cycle regimen highly emetogenic chemotherapy adequate liver function define total bilirubin less equal 1.5 time upper limit normal age AST/ALT le equal upper limit normal age adequate kidney function define creatinine clearance GFR great equal 70mL/min/1.73m2 serum creatinine base age/gender follow : Maximum serum creatinine 2 &lt; 6 year : Male &amp; Female 0.8 6 &lt; 10 year : Male &amp; Female 1 10 &lt; 13 year : Male &amp; Female 1.2 13 &lt; 16 year : Male 1.5 Female 1.4 &gt; 16 year : Male 1.7 Female 1.4 know QTc prolongation cardiac arrhythmia current treatment another antipsychotic ( example : risperidone , quetiapine , clozapine ) prior adverse reaction either olanzapine aprepitant plan two cycle chemotherapy include ifosfamide ( patient may receive ifosfamide part his/her overall treatment plan study cycle )</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>olanzapine</keyword>
	<keyword>Nausea vomit</keyword>
	<keyword>aprepitant</keyword>
	<keyword>pediatrics</keyword>
</DOC>